ABSTRACT Background: While the various antitumororal activities of adiponectin as an adipocyte-derived hormone well studied, it is speculated that there is a crosstalk between adiponectin and esterogen receptor (ER) signaling. To test this hypothesis we evaluate the possible correlation between serum level of adiponectin with two estrogen receptors (ERα and ERβ) gene expression in breast cancer patients. Methods: In this case-control study, 70 women with breast cancer participated with different grades of obesity (36 none obese, BMI < 25 kg/m2 and 34 obese, BMI ≥ 25 kg/m2).The mean age of Participants was 44.53 yr ± 1.79 yr (21 yr - 70 yr) .Serum level of adiponectin determined by ELISA. Following quantitative expression of estrogen receptors mRNA in tumor tissues was evaluated by Real-time PCR. Results: We find a significant reverse correlation between serum level of Adiponectin and ERα mRNA (r = –0.229, n = 64, p = 0.035) but no correlation was between adiponectin and ERβ in samples (p = 0.228). The lower adiponectin multiplied the odds of having higher ERα mRNA level by a factor of OR = 4.33, 1.28 - 14.6, 95% confidence interval (CI) as compared with those that displayed a moderate or higher serum level of adiponectin (>7.02 ng/ml). The same odds for next estrogen receptor, ERβ, was not greater than unity (OR = 0.31, 0.06 - 1.56, 95% CI). Conclusion: According to the obtained results, it is speculated that as adiponectin can affect ERs gene expression, so affecting the steroid receptor signaling can be proposed as a new underling mechanism of action for this adipokine in breast cancer pathogenesis especially in obese ones.
Cite this paper
R. Esfahlan, N. Zarghami, S. Valiyari, H. Kamel, M. Daneshvar, A. Esfahlan, M. Mobasseri and K. Nejati-Koshki, "Adiponectin Can Affect ER Signaling in Obese Breast Cancer Patients," Journal of Cancer Therapy, Vol. 3 No. 1, 2012, pp. 115-121. doi: 10.4236/jct.2012.31015.
 A. Jemal, R. Siegel, E. Ward, Y. Hao, J. Xu, T. Murray, et al., “Cancer Statistics, 2008,” CA: Cancer Journal for Clinicians, Vol. 58, No. 2, 2000, pp. 71-96.
 J. M. Holly and C. M. Perks, “Cancer as an Endocrine Problem,” Best Practice & Research Clinical Endocrinology & Metabolism, Vol. 22, No. 4, 2008, pp. 539-550.
 W. K. Hou, Y. X. Xu, T. Yu, L. Zhang, W. W. Zhang, C. L. Fu, et al., “Adipocytokines and Breast Cancer Risk,” Chinese Medical Journal (English Edition), Vol. 102, No. 18, 2007, pp. 1592-1596.
 D. Housa, J. Housova, Z. Vernerova and M. Haluzik, “Adipocytokines and Cancer,” Physiological Research, Vol. 55, No. 3, 2006, pp. 233-244.
 S. Loi, R. L. Milne, M. L. Friedlander, M. R. McCredie, G. G. Giles, J. L. Hopper, et al., “Obesity and Outcomes in Premenopausal and Postmenopausal Breast Cancer,” Cancer Epidemiology, Biomarkers & Prevention, Vol. 14, No. 7, 2005, pp. 1686-1691.
 M. Rahmati-Yamchi, N. Zarghami, M. Rahbani and A. Montazeri, “Plasma Leptin, hTERT Gene Expression, and Anthropometric Measures in Obese and Non-Obese Women with Breast Cancer,” Breast Cancer, Vol. 5, 2011, pp. 27-35.
 J. Matthews and J. A. Gustafsson, “Estrogen Signaling: A Subtle Balance between ER Alpha and ER Beta,” Molecular Interventions, Vol. 3, No. 5, 2003, pp. 281-292.
 V. Speirs, A. T. Parkes, M. J. Kerin, D. S. Walton, P. J. Carleton, J. N. Fox and S. L. Atkin, “Coexpression of Estrogen Receptor a and β Poor Prognostic Factors in Human Breast Cancer?” Cancer Research, Vol. 59, No. 3, 1999, pp. 525-528.
 C. Zhao, K. Dahlman-Wright and J. A. Gustafsson, “Estrogen Receptor Beta: An Overview and Update,” Nuclear Receptor Signaling, Vol. 6, 2008, p. e003.
 R. Jahanban-Esfahlan, N. Zarghami, A. Jahanban Esfahlan, M. Mollazadeh, K. Nejati and M. Nasiri, “The Possible Impact of Obesity on Androgen, Progesterone and Estrogen Receptors (ERα and ERβ) Gene Expression in Breast Cancer Patients,” Breast Cancer, Vol. 5, 2011, pp. 227-237.
 R. Jahanban Esfahla, N. Zarghami, M. Rahmati Yamchi, A. Monfaredan, et al., “Quantification Of Steroid Receptors Gene Expression in Breast Cancer Patients: Possible Correlation with Serum Level of Adipocytokines,” Journal of Cancer Therapy, in Press, 2011.
 M. Artac and K. Altundag, “Leptin and Breast Cancer: An Overview,” Medical Oncology, 2011, pp. 1-8.
 B. Sonmez, M. Seker, A. Bilici, E. F. Yavuz, B. B. Oven Ustaalioglu, M. Gumus, et al., “Is There Any Correlation Among Adiponectin Levels in Serum, Tumor Tissue and Normal Tissue of the Same Patients with Breast Cancer?” Journal of BUON, Vol. 16, No. 2, 2011, pp. 227-232.
 W. Zhu, K. K. Cheng, P. M. Vanhoutte, K. S. Lam and A. Xu, “Vascular Effects of Adiponectin: Molecular Mechanisms and Potential Therapeutic Intervention,” Clinical Science, Vol. 114, No. 5, 2008, pp. 361-374.
 I. Kelesidis, T. Kelesidis and C. S. Mantzoros, “Adiponectin and Cancer: A Systematic Review,” British Journal of Cancer, Vol. 94, No. 9, 2006, pp. 1221-1225.
 G. H. Pfeiler, C. Buechler, M. Neumeier, A. Schaffler, G. Schmitz, O. Ortmann, et al., “Adiponectin Effects on Human Breast Cancer Cells Are Dependent on 17-Beta Estradiol,” Oncology Reports, Vol. 19, No. 3, 2008, pp. 787-793.
 O. Treeck, C. Lattrich, I. Juhasz-Boess, S. Buchholz, G. Pfeiler and O. Ortmann, “Adiponectin Differentially Affects Gene Expression in Human Mammary Epithelial and Breast Cancer Cells,” British Journal of Cancer, Vol. 99, No. 8, 2008, pp. 1246-1250.
 J. D. Arditi, M. Venihaki, K. P. Karalis and G. P. Chrousos, “Antiproliferative Effect of Adiponectin on MCF7 Breast Cancer Cells: A Potential Hormonal Link between Obesity and Cancer,” Hormone Metabolism Research, Vol. 39, No. 1, 2007, pp. 9-13.
 M. M. N. Dieudonne, M. Bussiere, S. E. Dos, M. C. Leneveu, Y. Giudicelli and R. Pecquery, “Adiponectin Mediates Antiproliferative and Apoptotic Responses in Human MCF7 Breast Cancer Cells,” Biochemical and Biophysical Research Communications, Vol. 345, No. 1, 2006, pp. 271-279.